Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional StudyArticle

bcr-2014-205971 1..3Correspondence to Dr Robert Mechera, [email protected] Accepted 10 April 2015 To cite: Mechera R, Graf L, Oertli D, et al. BMJ Case Rep Published online:

Haemophilia and your child 4 What is haemophilia? 5 What causes haemophilia? 5 Can females have haemophilia? 6 Carriers 8 Who is affected by haemophilia? 9 How severe is

What is haemophilia A?What happens in the blood of a person with haemophilia A? In a healthy person, proteins called clotting factors work together to form a blood clot and

B1 NHS England /B05/S/a © NHS Commissioning Board, 2013 The NHS Commissioning Board is now known as NHS England B05/S/a 2013/14 NHS STANDARD CONTRACT FOR HAEMOPHILIA

Case report Dental management of patients with haemophilia in the era of recombinant treatments: increased efficacy and decreased clinical risk antonio Liras, Luis romeu

07 June 2013 2 NOTICE These Standards are designed to provide minimum guidelines for European Haemophilia Centres. These Standards are not intended to establish best practices

Core SmPC factor VIII products rev. 330 Churchill Place Canary Wharf London E14 5EU United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile

Core SPC factor VIII products7 Westferry Circus Canary Wharf London E14 4HB United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail [email protected]